검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | reverse transcriptase-polymerase chain reaction (reverse transcriptase-polymerase chain reaction) ICON plc·Leukemia ORR 58.33% |
|---|---|
Overview Program | reverse transcriptase-polymerase chain reaction |
Overview Company | ICON plc |
Overview Modality | ANTIBODY |
Overview Target | Leukemia |
Overview Indication | Prostate Cancer |
Overview Phase | PHASE_1 |
Overview Status | DISCONTINUED |
MoA Mechanism | and has demonstrated differentiation-inducing activity in vitro and in limited clinical reports |
MoA Biomarker | Biomarker |
PK/PD Species | Rat |
PK/PD Animal (cat.) | Rat, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Rat |
Toxicology Animal (cat.) | Rat, In vitro |
Toxicology Major finding | Ensitrelvir for Covid-19 Postexposure Prophylaxis in Household Contacts.. Ensitrelvir, an oral inhibitor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 3C-like protease, is approved in Japan for the treatment of mild-to-moderate coronavirus disease 2019 (Covid-19). Previously, no antiviral agents were approved for postexposure prophylaxis in household contacts of patients with Cov… |
Clinical Primary efficacy | ORR 58.33% |
Clinical ORR | 58.33% |
Clinical Result source | ClinicalTrials.gov NCT00470184 |
Clinical Data Tier / Score | A · 29 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 12일 (2일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | reverse transcriptase-polymerase chain reaction (reverse transcriptase-polymerase chain reaction) ICON plc·Leukemia ORR 58.33% |
|---|---|
Overview Program | reverse transcriptase-polymerase chain reaction |
Overview Company | ICON plc |
Overview Modality | ANTIBODY |
Overview Target | Leukemia |
Overview Indication | Prostate Cancer |
Overview Phase | PHASE_1 |
Overview Status | DISCONTINUED |
MoA Mechanism | and has demonstrated differentiation-inducing activity in vitro and in limited clinical reports |
MoA Biomarker | Biomarker |
PK/PD Species | Rat |
PK/PD Animal (cat.) | Rat, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Rat |
Toxicology Animal (cat.) | Rat, In vitro |
Toxicology Major finding | Ensitrelvir for Covid-19 Postexposure Prophylaxis in Household Contacts.. Ensitrelvir, an oral inhibitor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 3C-like protease, is approved in Japan for the treatment of mild-to-moderate coronavirus disease 2019 (Covid-19). Previously, no antiviral agents were approved for postexposure prophylaxis in household contacts of patients with Cov… |
Clinical Primary efficacy | ORR 58.33% |
Clinical ORR | 58.33% |
Clinical Result source | ClinicalTrials.gov NCT00470184 |
Clinical Data Tier / Score | A · 29 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 12일 (2일 전) |
추천 비교
추천 비교